Reported 7 months ago
Moderna, known for its COVID-19 vaccine, has been utilizing AI technology for years to enhance its efficiency in the laboratory. Recently, the company expanded its collaboration with OpenAI, with AI expected to advance drug discovery processes and increase overall efficiency. While Moderna's vaccine revenue is declining post-pandemic, its pipeline and AI investments suggest potential for revenue growth. The company's use of ChatGPT tools has already shown cost-saving benefits, making it more efficient. While the AI investment is promising, investors should also consider Moderna's pipeline and long-term potential when determining if the stock is a buy.
Source: YAHOO